Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients (eDIVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03520855 |
|
Recruitment Status :
Recruiting
First Posted : May 11, 2018
Last Update Posted : May 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this study is to evaluate the contribution of a serious game in the reinforcement of knowledge acquired during therapeutic education of type 1 diabetes paediatric patients.
This evaluation will take place within 3 months of the diagnosis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 1 Diabetes | Other: Serious game Behavioral: ETP | Not Applicable |
Type 1 diabetes gather multiple metabolic pathologies secondary to a deficiency in insulin secretion or insulin action, characterized by chronic hyperglycaemia. Diagnosis is based on fasting glycaemia above 1.26 g/l or above 2 g/l any time of the day.
Currently, it is recommend initial therapeutic education additionally to insulin therapy, in the type 1 diabetes care. Initial therapeutic education's role is to develop 3 specific skills : self-care skills, safety skills and adaptation skills. This approach gives to the patient the abilities to monitor himself, to handle emergency situations and to modify his lifestyle to treat his disease correctly.
In the serious game, the patient will directly evolve in a virtual environment, with places reflecting his real life such as paediatric diabetology centre, hospital, home, school. He will have to complete quests with his own virtual avatar, that reflect situations his disease can confront him to. Each quest ends with a questionnaire.
The principal objective of this research is to evaluation the contribution of a serious game (DIVE) in the reinforcement of knowledge acquired during therapeutic education of type 1 diabetes paediatric patients.
This research is designed in two arms, gathering 100 patients, each arm has 50 patients. Both arms benefit initial therapeutic education, except the experimental group which is added a serious game .
To measure the impact of the serious game,investigators will compare HbA1c dosage between groups (with HPLC technique), 3 months after diagnosis; but also the number of hypo or hyperglycaemia in the month before M3 final consultation. They will also evaluate self-care skills and safety skills with role-plays at the end of hospitalisation and 3 months later. Technical gestures will also be evaluated by referent nurses.
Evaluation of the patient's well-being will take place with two types of questionnaire, WHO-Five and DOQLY during M3 final consultation.
This research will bring essential information on the development of video games in other paediatric chronic diseases, as a first step in the development of the use of video games in therapeutic care of type 1 diabetes.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | Contribution of a Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients |
| Actual Study Start Date : | April 3, 2019 |
| Estimated Primary Completion Date : | April 2022 |
| Estimated Study Completion Date : | July 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ETP + Serious game
patients receiving the serious game additionally to the classic therapeutic education
|
Other: Serious game
DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour. Behavioral: ETP Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book. Health education sessions will also be taught by nurses. |
|
Active Comparator: ETP
patients under classic therapeutic education
|
Behavioral: ETP
Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book. Health education sessions will also be taught by nurses. |
- Diapason questionnaire (Aide aux Jeunes Diabètes) [ Time Frame: 3 months ]50 questions (disease, treatment, food,…)
- HbA1c dosage [ Time Frame: 3 months ]Glycemia follow-up with a self-monitoring book in each arm
- Number of hypo or hyperglycaemia [ Time Frame: 3 months ]Statement of the number of hypo or hyperglycaemia within the months preceding the consultation
- Evaluation of self-care skills [ Time Frame: 3 months ]Evaluation of self-care skills with role-plays and assessment of feelings of competence from their DT1 (scorecard, Barrow chart )
- Evaluation of well-being with WHOFIVE [ Time Frame: 3 months ]Evaluation of patient's well-being with auto-questionnaires
- Evaluation of well-being with DQOLY [ Time Frame: 3 months ]Evaluation of patient's well-being with auto-questionnaires
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 10 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Child aged from 10 to 17 and 8 months
- Child with a type 1 diabetes (inclusion within 96 hours following the diagnosis, except for patients admitted to intensive care for whom an additional 48-hour period is accepted for their inclusion). Diagnosis will be confirmed based on one of the classic diagnostic criteria: venous glycaemia above 2 g / l, presence of polyuropolydipsic syndrome, presence of weight loss, presence of ketonuria (equivalent to at least one cross in urine or> 0.5mmol / l in blood)
- Child with internet access and with a computer or a tablet or a mobile phone in at least one of the two parents or legal representative(s)
- Informed consent signed by parents or legal representative(s) (only one parent possible)
- Beneficiary of a social security system
Exclusion Criteria:
- No internet access or no computer or no tablet or no mobile phone at home available
- No French language proficiency of the infant or legal representative(s)
- Inability to understand the game's instructions
- Inability to understand or fill the consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03520855
| Contact: Nadine Lepage, MD, PhD | +33 1 87 89 20 68 | nadine.lepage@aphp.fr | |
| Contact: Sandra COLAS | + 33 1 71 19 64 32 | sandra.colas@aphp.fr |
| France | |
| Necker Hospital | Recruiting |
| Paris, France, 75015 | |
| Contact: Jacques BELTRAND, MD, PhD 01 44 38 15 45 jacques.beltrand@aphp.fr | |
| Principal Investigator: | Jacques BELTRAND, MD, PhD | Assistance Publique - Hôpitaux de Paris |
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT03520855 |
| Other Study ID Numbers: |
K150907J 2017-A02052-51 ( Registry Identifier: ID-RCB ) |
| First Posted: | May 11, 2018 Key Record Dates |
| Last Update Posted: | May 18, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Type 1 Diabetes Paediatrics patients |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |